CN104352293A - Drug eluting stent capable of reducing late thrombosis - Google Patents
Drug eluting stent capable of reducing late thrombosis Download PDFInfo
- Publication number
- CN104352293A CN104352293A CN201410690060.0A CN201410690060A CN104352293A CN 104352293 A CN104352293 A CN 104352293A CN 201410690060 A CN201410690060 A CN 201410690060A CN 104352293 A CN104352293 A CN 104352293A
- Authority
- CN
- China
- Prior art keywords
- stent
- restenosis
- medicine
- blood vessel
- drug eluting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
An intravascular stent is an effective interventional device for treating cardiovascular hemadostenosis or blockage, and a drug eluting stent is taken as a stent of newest generation, so that the restenosis rate after stent implantation is remarkably reduced, and thus the occurrence rate of stent thrombosis is increased. The reasons are as follows: firstly, a coating medicine of the stent is capable of inhibiting regeneration of vascular smooth muscle and growth of endothelial cells, so that endothelialization of a vascular wall is incomplete and a cell matrix is exposed, and thus blood clotting response is promoted; after stent implantation, regional blood disorder is caused, so that blood clotting response is further promoted, and thus stent thrombosis is caused and a blood vessel in the stent generates restenosis. The drug eluting stent aims at the problems and provides a new intravascular stent provided with perforated design, so that the local turbulence in the stent is reduced and the occurrence rate of thrombus in the blood vessel is reduced under the condition that the strength of the stent is guaranteed, and thus restenosis in the blood vessel is prevented.
Description
Technical field
The present invention relates to a kind of endovascular stent, particularly a kind of bracket for eluting medicament.
Background technology
Cardiovascular disease caused by atherosclerosis is as more and more higher in coronary artery disease incidence rate, becomes one of disease of serious harm human health.The Main Means of this disease of current treatment makes narrow, inaccessible vasodilation through intervention support implanted prosthetics, lead to.Support, as the tube of support blood vessels, completely solves the restenosis caused by post-surgical vascular elastical retraction, makes postoperative restenosis rate obviously reduce about 20% ~ 30%.In addition, the advantages such as it also has, and curative effect is high, wound is little, risk is low, few intercurrent disease, hospital stays are short, become the preferred option of such disease for the treatment of at present.Bare bracket is placed and vascular smooth muscle cell can be caused to produce certain hypertrophy to the stimulation of blood vessel, can cause the again inaccessible of blood vessel (especially small-diameter intravascular), force patient's second operation, add patient's misery and family burden.In order to solve the restenosis that proliferation of smooth muscle causes, people design propagation and the migration that coating stent of medicine can suppress smooth muscle, but also suppress the propagation of endotheliocyte simultaneously, postpone vessel endothelialisation, postpone the normal healing of blood vessel.Endothelialization is incomplete, and extracellular matrix is highly exposed and can activate Coagulation test, forms thrombosis, and thrombosis assembles in bulk can cause Restenosis again.Data statistics shows, the curative effect of implantation of drug-eluting stent restenosis is better than bare metal stent, but thrombus in vivo incidence rate significantly increases.Bracket for eluting medicament still remains the vascular restenosis rate of 15% to 20% after implanting, wherein thrombosis is the key factor causing restenosis, and therefore, the thrombosis in bracket for eluting medicament is significant problem urgently to be resolved hurrily.
In order to solve the thrombosis problem of bracket for eluting medicament, adopting postoperative use anticoagulant clinically, reducing thrombosis, but can not fundamentally solve.Along with hemodynamic development, research shows, high local flow velocities and the high boundary shear stress of close blood vessel wall can make thrombin secreting rate reduce, and the secreting rate of anticoagulant, thrombolytic agent etc. is increased; Meanwhile, the design of scaffolding thread, the structure of support are again the keys affecting regional flow.Therefore, design a bracket for eluting medicament, the Hydrodynamic character of local can be optimized, improve flow velocity and the boundary shear stress of local in support, thus reduce thrombosis.
Summary of the invention
The present invention is directed to bracket for eluting medicament and implant the rear thrombotic problem of long-term existence, a kind of new intravascular drug FirebirdTM is proposed, the hemodynamic responses that implant frame is caused reduces, thus the thrombotic probability of promotion is reduced, thus prevents the generation of stent restenosis.
In order to solve above-mentioned hemodynamic responses problem, the present invention is achieved by the following technical solutions: a kind of novel endovascular stent, and the cross section of this scaffolding thread is a kind of profile design of perforation.This design inspiration comes from after dam opens a sluice gate and draws out some water, and the water velocity in downstream can be made to raise, and the earth of downstream siltation breaks up and then illustrates that boundary shear stress increases.
Ensureing that scaffolding thread itself can not occur because of under perforated design causes the prerequisite ruptured, the perforation size of described endovascular stent can be the arbitrary value lower than maximum upper limit, and perforation shape can be arbitrary shape, such as circular, oval, square.
The weaving manner of described endovascular stent or shape can adopt weaving manner or the shape of any one existing intravascular stent.
Described endovascular stent can be metal rack also can be coating stent of medicine.
Pass through technique scheme, compared with commercial racks, the Hemodynamic response after stenter to implant blood vessel can be optimized, the blood flow rate of the forward and backward regional area of scaffolding thread is raised relatively, boundary shear stress increases relatively, thus reduce the thrombotic factor of promotion, reach the object preventing Restenosis.
Accompanying drawing illustrates:
Fig. 1 is front view of the present invention and partial enlarged drawing;
Fig. 2 is 3D rotary stereo figure of the present invention.
Detailed description of the invention:
Specific embodiment of the invention scheme is described as follows:
As shown in Figure 1, coating stent of medicine 1 disclosed by the invention has the shape of intravascular stent, and it is made up of two large divisions: holder part and perforated design part.Wherein holder part can be metal rack or biodegradable stent, the weaving method of published intravascular stent or shape before its weaving method or shape can adopt.
Claims (5)
1. ensure scaffolding thread itself can not occur because of perforated design cause rupture prerequisite under, the perforation size of described intravascular drug FirebirdTM can be the arbitrary value lower than maximum upper limit, and perforation shape can be arbitrary shape, such as circular, oval, square.
2. coating stent of medicine according to claim 1, is characterized in that, the holder part of described coating stent of medicine can be metal rack also can be degradation material support.
3. coating stent of medicine according to claim 1, is characterized in that, described medication coat forms by polymer with by the ingredient of polymer overmold.
4. coating stent of medicine according to claim 1, is characterized in that, the ingredient of described medication coat is the combination of a class in statins, rapamycin class, taxanes, heparin class medicine or 2-4 class.
5. coating stent of medicine according to claim 1, is characterized in that, the weaving method of published intravascular stent or shape before the weaving method of described coating stent of medicine or shape can adopt.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410690060.0A CN104352293A (en) | 2014-11-25 | 2014-11-25 | Drug eluting stent capable of reducing late thrombosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410690060.0A CN104352293A (en) | 2014-11-25 | 2014-11-25 | Drug eluting stent capable of reducing late thrombosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104352293A true CN104352293A (en) | 2015-02-18 |
Family
ID=52519675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410690060.0A Pending CN104352293A (en) | 2014-11-25 | 2014-11-25 | Drug eluting stent capable of reducing late thrombosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104352293A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109330753A (en) * | 2018-08-20 | 2019-02-15 | 江苏大学 | A kind of carried stent improving blood circulation |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010032011A1 (en) * | 1999-07-20 | 2001-10-18 | Stanford Ulf Harry | Expandable stent with array of relief cuts |
| CN2503865Y (en) * | 2001-08-01 | 2002-08-07 | 蒲忠杰 | Medicine released support |
| CN1709210A (en) * | 2005-07-08 | 2005-12-21 | 东南大学 | Microporous structure blood vessel stent |
| CN200970281Y (en) * | 2006-08-28 | 2007-11-07 | 北京乐普医疗器械有限公司 | Medicine storage and medicine releasing structure for medicinal elution device |
| CN101273926A (en) * | 2007-03-28 | 2008-10-01 | 科迪斯公司 | Short term sustained drug-delivery system for implantable medical devices and method of making the same |
-
2014
- 2014-11-25 CN CN201410690060.0A patent/CN104352293A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010032011A1 (en) * | 1999-07-20 | 2001-10-18 | Stanford Ulf Harry | Expandable stent with array of relief cuts |
| CN2503865Y (en) * | 2001-08-01 | 2002-08-07 | 蒲忠杰 | Medicine released support |
| CN1709210A (en) * | 2005-07-08 | 2005-12-21 | 东南大学 | Microporous structure blood vessel stent |
| CN200970281Y (en) * | 2006-08-28 | 2007-11-07 | 北京乐普医疗器械有限公司 | Medicine storage and medicine releasing structure for medicinal elution device |
| CN101273926A (en) * | 2007-03-28 | 2008-10-01 | 科迪斯公司 | Short term sustained drug-delivery system for implantable medical devices and method of making the same |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109330753A (en) * | 2018-08-20 | 2019-02-15 | 江苏大学 | A kind of carried stent improving blood circulation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kitrou et al. | Drug-eluting versus plain balloon angioplasty for the treatment of failing dialysis access: final results and cost-effectiveness analysis from a prospective randomized controlled trial (NCT01174472) | |
| Kundu | Review of central venous disease in hemodialysis patients | |
| CN203885667U (en) | Stent | |
| Foin et al. | Location of side branch access critically affects results in bifurcation stenting: insights from bench modeling and computational flow simulation | |
| CN202843856U (en) | Recyclable stent for coronary disease interventional therapy | |
| Luo et al. | Stent-grafts for the treatment of TIPS dysfunction: fluency stent vs Wallgraft stent | |
| Kobo et al. | Modern stents: where are we going? | |
| Yaowang et al. | Drug-coated balloon versus drug-eluting stent for treating de novo coronary lesions in large vessels: a meta-analysis of clinical trials | |
| CN104352293A (en) | Drug eluting stent capable of reducing late thrombosis | |
| CN101214397A (en) | Medicament elution bracket for promoting esoderma repair and preventing vascular restenosis | |
| Dolmatch et al. | Prospective, randomized, multicenter clinical study comparing a self-expanding covered stent to percutaneous transluminal angioplasty for treatment of upper extremity hemodialysis arteriovenous fistula stenosis | |
| Bil et al. | Assessment of vascular response to Bi OSS LIM C® stents vs Orsiro® stents in the porcine coronary artery model | |
| Mori et al. | Bioresorbable vascular scaffolds: Implication of very late scaffold thrombosis | |
| CN108245216A (en) | A kind of aneurysm treatment system | |
| CN205083716U (en) | Covered stent | |
| CN104983492A (en) | Spraying liner structure and method for assisting in spraying medicine on absorbable stent | |
| CN204909753U (en) | Assist and to absorb spraying lining structure that support carries out medicine spraying | |
| CN208989271U (en) | A kind of degradable local dense net bracket | |
| Silvestre et al. | Endovascular treatment of occlusive central venous disease: one center's experience | |
| CN209827116U (en) | Recyclable medicine support | |
| Aboodi et al. | Long‐term impact of balloon postdilatation on neointimal formation: An experimental comparative study between second‐generation self‐expanding versus balloon‐expandable stent technologies | |
| Corballis et al. | Optical coherence tomographic study of a chronically retained coronary guidewire | |
| Fajadet et al. | First-in-Man trial of a drug-free bioresorbable stent designed to minimize the duration of coronary artery scaffolding | |
| CN107233150A (en) | A kind of mesoporous silicon oxide biodegradable stent and preparation method thereof | |
| Gąsior et al. | Early scaffold strut coverage in ultra-high molecular weight amorphous PLLA sirolimus-eluting bioresorbable scaffolds: impact of strut thickness assessed in normal porcine coronary arteries |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150218 |